Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Zevra Therapeutics, Inc. has granted options to purchase a total of 38,000 shares of common stock to two new employees as part of its 2023 Employment Inducement Award Plan [1][2] - Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee's start date, and the remaining 75% vesting in three equal annual installments [1] - The awards were approved by the Compensation Committee of the Board of Directors and are intended as an inducement for new employees [2] Company Overview - Zevra Therapeutics, Inc. is a commercial-stage company focused on developing therapies for rare diseases that have limited or no treatment options [3] - The company's mission is to provide life-changing therapeutics to individuals living with rare diseases through innovative, data-driven development and commercialization strategies [3]